Difference between revisions of "HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli"
| [unchecked revision] | [unchecked revision] |
Bailey.Glen (talk | contribs) |
Bailey.Glen (talk | contribs) |
||
| Line 8: | Line 8: | ||
Note: consider content on the overview page: Splenic B-cell Lymphoma/Leukemia, Unclassifiable | Note: consider content on the overview page: Splenic B-cell Lymphoma/Leukemia, Unclassifiable | ||
}}</blockquote> | }}</blockquote> | ||
| + | |||
| + | <span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span> | ||
| + | |||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
Revision as of 14:40, 13 December 2023
Haematolymphoid Tumours (5th ed.)
 | This page is under construction |
editHAEM5 Conversion NotesThis page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Hairy Cell Leukemia Variant.Note: consider content on the overview page: Splenic B-cell Lymphoma/Leukemia, Unclassifiable
(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)
Primary Author(s)*
- Snehal Patel, MD, PhD
Cancer Category / Type
Cancer Sub-Classification / Subtype
- Hairy Cell Leukemia Variant (HCLv)
Definition / Description of Disease
- HCLv is a rare chronic neoplasm of B-cell origin seen mostly in adults
- Name derives from clinicopathologic similarity to hairy cell leukemia (HCL) but with important differences
- Marked splenomegaly and marrow infiltration result in left flank discomfort, fatigue, and susceptibility to infections
- Most respond poorly to monotherapy with a purine analog or interferon alpha (used for HCL)
- Lack BRAF p.Val600Glu (V600E) mutations but some have mutations in MAP2K1
Synonyms / Terminology
- Prolymphocytic variant of hairy cell leukemia
Epidemiology / Prevalence
- ~0.2% of lymphoid leukemias
- Median age: 70 years
- Males:Females: 2:1
Clinical Features
Put your text here and fill in the table (Instruction: Can include references in the table)
| Signs and Symptoms | EXAMPLE Asymptomatic (incidental finding on complete blood counts)
EXAMPLE B-symptoms (weight loss, fever, night sweats) EXAMPLE Fatigue EXAMPLE Lymphadenopathy (uncommon) |
| Laboratory Findings | EXAMPLE Cytopenias
EXAMPLE Lymphocytosis (low level) |
editv4:Clinical FeaturesThe content below was from the old template. Please incorporate above.Signs & Symptoms
- Often asymptomatic
- Splenic enlargement and/or discomfort
- B-symptoms (weight loss, fever, night sweats)
- Fatigue
- Bruising
- Lymphadenopathy (uncommon)
Laboratory findings
- Cytopenias
- Lymphocytosis
- No monocytopenia
editUnassigned ReferencesThe following referenees were placed in the header. Please place them into the appropriate locations in the text.
Sites of Involvement
- Spleen (red pulp)
- Bone marrow
- Blood
- Liver
- Lymph node (uncommon)
editUnassigned ReferencesThe following referenees were placed in the header. Please place them into the appropriate locations in the text.
Morphologic Features
- Intermediate-sized lymphoid cells
- Abundant pale blue-grey lacey cytoplasm
- prolymphocytoid or blastoid nuclear features
- Cytoplasmic projections either villous or hair-like
- "Fried egg" appearance of cells (tissue sections)
- Interstitial pattern of marrow involvement
- No/minimal reticulin fibrosis
editUnassigned ReferencesThe following referenees were placed in the header. Please place them into the appropriate locations in the text.
Immunophenotype
| Finding | Marker |
|---|---|
| Positive (B-cell lineage markers) | CD19, CD20 (bright), CD22, CD79b, PAX5, FMC7, sIg (bright, monotypic) |
| Positive | CD11c, CD72, CD103 |
| Negative (HCL markers) | CD25, CD123, annexin A1, TRAP, BRAF V600E |
| Negative | CD5, CD10, CD23, CD38, CD43, BCL1 |
editUnassigned ReferencesThe following referenees were placed in the header. Please place them into the appropriate locations in the text.
Chromosomal Rearrangements (Gene Fusions)
Put your text here and fill in the table
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| EXAMPLE t(9;22)(q34;q11.2) | EXAMPLE 3'ABL1 / 5'BCR | EXAMPLE der(22) | EXAMPLE 20% (COSMIC)
EXAMPLE 30% (add reference) |
Yes | No | Yes | EXAMPLE
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). |
editv4:Chromosomal Rearrangements (Gene Fusions)The content below was from the old template. Please incorporate above.
- No consistent gene fusions
editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).Please incorporate this section into the relevant tables found in:
- Chromosomal Rearrangements (Gene Fusions)
- Individual Region Genomic Gain/Loss/LOH
- Characteristic Chromosomal Patterns
- Gene Mutations (SNV/INDEL)
Alteration Clinical Significance Note BRAF activating mutations Diagnostic Excludes HCL MAP2K1 activating mutations Prediction May be targetable with MEK inhibitors[3] IGHV4-34 Prediction Reduced response to purine analogs[4] IGHV4-34 Prognostic Less favorable prognosis[4]
- The 2017 WHO notes that whether cases that are classified as classical HCL but lack BRAF mutations and harbor MAP2K1 mutations are more like HCLv remains to be established
Individual Region Genomic Gain / Loss / LOH
Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.)
| Chr # | Gain / Loss / Amp / LOH | Minimal Region Genomic Coordinates [Genome Build] | Minimal Region Cytoband | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| EXAMPLE
7 |
EXAMPLE Loss | EXAMPLE
chr7:1- 159,335,973 [hg38] |
EXAMPLE
chr7 |
Yes | Yes | No | EXAMPLE
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). |
| EXAMPLE
8 |
EXAMPLE Gain | EXAMPLE
chr8:1-145,138,636 [hg38] |
EXAMPLE
chr8 |
No | No | No | EXAMPLE
Common recurrent secondary finding for t(8;21) (add reference). |
editv4:Genomic Gain/Loss/LOHThe content below was from the old template. Please incorporate above.
Chromosome Number Gain/Loss/Amp/LOH Consequence Prevalence 17p13 Loss TP53 deletion 42%[1] 11q22 Loss ATM deletion 22%[1]
Characteristic Chromosomal Patterns
Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)
| Chromosomal Pattern | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|
| EXAMPLE
Co-deletion of 1p and 18q |
Yes | No | No | EXAMPLE:
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). |
editv4:Characteristic Chromosomal Aberrations / PatternsThe content below was from the old template. Please incorporate above.
Gene Mutations (SNV / INDEL)
Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)
| Gene; Genetic Alteration | Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) | Prevalence (COSMIC / TCGA / Other) | Concomitant Mutations | Mutually Exclusive Mutations | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|---|
| EXAMPLE: TP53; Variable LOF mutations
EXAMPLE: EGFR; Exon 20 mutations EXAMPLE: BRAF; Activating mutations |
EXAMPLE: TSG | EXAMPLE: 20% (COSMIC)
EXAMPLE: 30% (add Reference) |
EXAMPLE: IDH1 R123H | EXAMPLE: EGFR amplification | EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).
|
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
editv4:Gene Mutations (SNV/INDEL)The content below was from the old template. Please incorporate above.
Gene* Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other) Prevalence MAP2K1 Oncogene GOF 7-50%[1][6][7][8][9] TP53 Tumor Suppressor LOF 29%[8] - 38%[7] KMT2C Tumor Suppressor LOF 25%[7] KDM6A Tumor Suppressor LOF 13%[7] - 50%[9] ARID1A Tumor Suppressor LOF 13%[7] - 25%[9] CREBBP Tumor Suppressor LOF 13%[7] - 25%[9] CCND3 Oncogene change of function 13%[7] U2AF Oncogene change of function 13%[7] ‡Specific mutations in these genes can be found in cBioPortal and COSMIC.
- There is wide variation in the reported prevalence of MAP2K1 mutations across studies for unclear reasons
Epigenomic Alterations
- Epigenetic dysregulation is expected in a subset of HCLv due to mutations in epigenetic regulators:
- KMT2C is a histone methyltransferase
- KDM6A is a histone demethylase
- CREBBP is a histone acetyltransferase
- ARID1A is a SWI/SNF family member
Genes and Main Pathways Involved
Put your text here and fill in the table (Instructions: Can include references in the table.)
| Gene; Genetic Alteration | Pathway | Pathophysiologic Outcome |
|---|---|---|
| EXAMPLE: BRAF and MAP2K1; Activating mutations | EXAMPLE: MAPK signaling | EXAMPLE: Increased cell growth and proliferation |
| EXAMPLE: CDKN2A; Inactivating mutations | EXAMPLE: Cell cycle regulation | EXAMPLE: Unregulated cell division |
| EXAMPLE: KMT2C and ARID1A; Inactivating mutations | EXAMPLE: Histone modification, chromatin remodeling | EXAMPLE: Abnormal gene expression program |
editv4:Genes and Main Pathways InvolvedThe content below was from the old template. Please incorporate above.
Molecular feature Pathway Physiologic outcome MAP2K1 activating mutations MAPK signaling Unregulated cell growth and proliferation KMT2C, KDM6A, CREBBP, and ARID1A LOF mutations Histone modification, chromatin remodeling Abnormal gene expression program TP53 LOF mutations DNA damage, apoptosis Cell survival and genomic instability
Genetic Diagnostic Testing Methods
- HCLv is a provisional entity and definitive diagnostic criteria have not been determined
- BRAF p.Val600Glu testing may be useful diagnostically in limited situations to exclude HCL
- BRAF p.Val600Glu may be detected by IHC using a mutant-specific antibody[10][11] or various molecular methods (NGS, real-time PCR, massARRAY, etc.)
- The mutant-specific antibody does not detect other BRAF mutations
- BRAF p.Val600Glu and Non-p.Val600Glu mutations and MAP2K1 mutations can be interrogated with NGS in a single assay[2]
- IGHV4-34 utilization can be detected by NGS and Sanger sequencing of IgH mRNA
Familial Forms
- Not described
Additional Information
- N/A
Links
References
(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Angelova, Evgeniya A.; et al. (2018). "Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 31 (11): 1717–1732. doi:10.1038/s41379-018-0093-8. ISSN 1530-0285. PMID 29955146.
- ↑ 2.0 2.1 2.2 2.3 2.4 Maitre, Elsa; et al. (2019). "Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment". American Journal of Hematology. 94 (12): 1413–1422. doi:10.1002/ajh.25653. ISSN 0361-8609.
- ↑ Andritsos, Leslie A.; et al. (2018). "Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia". Leukemia & Lymphoma. 59 (4): 1008–1011. doi:10.1080/10428194.2017.1365853. ISSN 1042-8194.
- ↑ 4.0 4.1 4.2 Arons, Evgeny; et al. (2009). "VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy". Blood. 114 (21): 4687–4695. doi:10.1182/blood-2009-01-201731. ISSN 0006-4971. PMC 2780305. PMID 19745070.CS1 maint: PMC format (link)
- ↑ Xi, Liqiang; et al. (2012). "Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation". Blood. 119 (14): 3330–3332. doi:10.1182/blood-2011-09-379339. ISSN 0006-4971. PMC 3321859. PMID 22210875.CS1 maint: PMC format (link)
- ↑ Mason, Emily F.; et al. (2017). "Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant". Leukemia & Lymphoma. 58 (1): 233–236. doi:10.1080/10428194.2016.1185786. ISSN 1029-2403. PMID 27241017.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Durham, Benjamin H.; et al. (2017). "Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations". Blood. 130 (14): 1644–1648. doi:10.1182/blood-2017-01-765107. ISSN 1528-0020. PMC 5630011. PMID 28801450.
- ↑ 8.0 8.1 Waterfall, Joshua J.; et al. (2014). "High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias". Nature Genetics. 46 (1): 8–10. doi:10.1038/ng.2828. ISSN 1546-1718. PMC 3905739. PMID 24241536.
- ↑ 9.0 9.1 9.2 9.3 Maitre, Elsa; et al. (2018). "New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes". Oncotarget. 9 (48): 28866–28876. doi:10.18632/oncotarget.25601. ISSN 1949-2553. PMC 6034755. PMID 29989027.
- ↑ Ritterhouse, Lauren L.; et al. (2015). "BRAF V600E mutation-specific antibody: A review". Seminars in Diagnostic Pathology. 32 (5): 400–408. doi:10.1053/j.semdp.2015.02.010.
- ↑ Loo, Eric; et al. (2017). "BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry". Applied Immunohistochemistry & Molecular Morphology: 1. doi:10.1097/PAI.0000000000000516. ISSN 1541-2016.
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. *Citation of this Page: “Splenic B-cell lymphoma/leukaemia with prominent nucleoli”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/13/2023, https://ccga.io/index.php/HAEM5:Splenic_B-cell_lymphoma/leukaemia_with_prominent_nucleoli.